Current Cardiovascular Risk Reports

, Volume 6, Issue 5, pp 443–449

Dyslipidemia Management for Secondary Prevention in Women with Cardiovascular Disease: What Can We Expect From Nonpharmacologic Strategies?

  • Seamus Whelton
  • Grant V. Chow
  • M. Dominique Ashen
  • Roger S. Blumenthal
Secondary Intervention (JM Foody, Section Editor)

DOI: 10.1007/s12170-012-0254-0

Cite this article as:
Whelton, S., Chow, G.V., Ashen, M.D. et al. Curr Cardiovasc Risk Rep (2012) 6: 443. doi:10.1007/s12170-012-0254-0

Abstract

Cardiovascular disease is the leading cause of death in women and the treatment of dyslipidemia is a cornerstone of secondary prevention. Pharmacologic therapy with statins can lower LDL-C by 30 %–50 % and reduce the risk of recurrent coronary heart disease in both men and women. While significant reductions in LDL-C can be achieved with statin therapy, diet and lifestyle modification remain an essential part of the treatment regimen for cardiovascular disease. Moreover, a large proportion of the US population is sedentary, overweight, and does not consume a heart-healthy diet. Nonpharmacologic treatment strategies also improve other cardiovascular risk factors and are generally easily accessible. In this review, we examine the effect of nonpharmacologic therapy on lipids as part of the secondary prevention strategy of cardiovascular disease in women.

Keywords

WomenDyslipidemiasCardiovascular diseasesSecondary preventionDietLifestyle

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Seamus Whelton
    • 1
    • 2
  • Grant V. Chow
    • 2
  • M. Dominique Ashen
    • 2
  • Roger S. Blumenthal
    • 2
  1. 1.Welch Center for Prevention, Epidemiology and Clinical ResearchJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  2. 2.Johns Hopkins Ciccarone Center for the Prevention of Heart DiseaseBaltimoreUSA